Anti-Mouse CD366 (Tim-3) - Purified In vivo PLATINUM Functional Grade

Antibody Details

Product Details

Reactivity Species

Mouse

Host Species

Rat

Immunogen

This antibody was produced using recombinant mouse TIM-3

Product Concentration

≥ 5.0 mg/ml

Endotoxin Level

< 0.5 EU/mg as determined by the LAL method

Purity

≥98% monomer by analytical SEC

⋅

> 95% by SDS Page

Formulation

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.

Product Preparation

Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Pathogen Testing

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM™ antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Storage and Handling

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Shipping

Next Day 2-8°C

RRID

AB_2894397

Applications and Recommended Usage?
Quality Tested by Leinco

FC The suggested concentration for CD366 antibody (clone RMT3-23) for staining cells in flow cytometry is ≤ 1.0 μg per 10⁶ cells in a volume of 100 μl or 100μl of whole blood. Titration of the reagent is recommended for optimal performance for each application.

Other Applications Reported In Literature ?

B

IHC

Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity

Clone RMT2-23 recognizes an epitope on mouse Tim-3.

Antigen Distribution

Tim-3 is expressed on activated Th1 and Tc1 lymphocytes, CD11b+ macrophages, Tregs, NK cells, and mast cells.

Background

Tim-3 antibody, clone RMT3-23, recognizes T cell immunoglobulin and mucin domain-containing protein 3 (TIM3, also known as CD366), a TIM family member of immunoregulatory proteins. Tim-3 is a 60kDa type I transmembrane protein with an extracellular immunoglobulin and mucin-like domain and a cytoplasmic tyrosine phosphorylation motif. Tim-3 is expressed by IFNg-producing Th1 CD4 and Tc1 (cytotoxic) CD8 T cells¹, regulatory T cells (Tregs)², myeloid cells³, NK cells⁴, and mast cells⁵. Tim-3 is an inhibitory molecule that limits Th1-mediated inflammatory diseases, including a model of central nervous system inflammation (experimental autoimmune encephalomyelitis, EAE)¹, inflammatory bowel disease (IBD)⁶, and type I diabetes⁷. Tim-3 is also proposed to induce immunological tolerance⁷, promote Th1 apoptosis⁸, and regulate macrophage activation1. In addition, Tim-3 is upregulated on tumor-infiltrating lymphocytes, and coblockade of Tim-3 and immune checkpoint inhibitors, such as PD-1, is currently being investigated in clinical trials for the treatment of cancer⁹.

Antigen Details

Protein

Tim-3

Ligand/Receptor

Putative ligand on resting CD4+ lymphocytes

Function

May play a role in the development of immune responses and the development of Th1-mediated responses

PubMed

Tim-3

NCBI Gene Bank ID

171285

UniProt.org

Information on Uniprot.org

Research Area

Immunology

.

Inhibitory Molecules

References & Citations

1. Monney, L. et al. (2002)Nature 415, 536–541.

2. Gao, X. et al. (2012) PLOS ONE 7, e30676.

3. Anderson, A. C. et al. (2007) Science 318, 1141–1143.

4. Ndhlovu, L. C. et al. (2012) Blood 119, 3734–3743.

5. Phong, B. L. et al. J. (2015) Exp. Med. 212, 2289–2304.

6. Li, X. et al. (2010) Clin. Immunol. 134, 169–177.

7. Sanchez-Fueyo, A. et al. (2003) Nat. Immunol. 4, 1093–1101.

8. Zhu C, et al.. Nature Immunology. 2005; 6:1245–1252.

Technical Protocols